Anaplastic Thyroid Carcinoma, Version 2.2015.

Published

Journal Article

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.

Full Text

Duke Authors

Cited Authors

  • Haddad, RI; Lydiatt, WM; Ball, DW; Busaidy, NL; Byrd, D; Callender, G; Dickson, P; Duh, Q-Y; Ehya, H; Haymart, M; Hoh, C; Hunt, JP; Iagaru, A; Kandeel, F; Kopp, P; Lamonica, DM; McCaffrey, JC; Moley, JF; Parks, L; Raeburn, CD; Ridge, JA; Ringel, MD; Scheri, RP; Shah, JP; Smallridge, RC; Sturgeon, C; Wang, TN; Wirth, LJ; Hoffmann, KG; Hughes, M

Published Date

  • September 2015

Published In

Volume / Issue

  • 13 / 9

Start / End Page

  • 1140 - 1150

PubMed ID

  • 26358798

Pubmed Central ID

  • 26358798

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2015.0139

Language

  • eng

Conference Location

  • United States